NeoGenomics Puts MRD Front and Center in Q1 2026 While Raising Revenue Guidance

Overview: Solid top-line momentum with a leaner bottom line

NeoGenomics, a leading oncology diagnostic service provider, reported a first quarter of 2026 that reinforced the company’s growth trajectory without committing to a tidy EPS number in the press release. Consolidated revenue rose 11% year over year to $187 million, aided by a 14% uptick in clinical revenue and a standout 26% growth in next-generation sequencing (NGS). The company trimmed its net loss to $17 million and posted positive Adjusted EBITDA of $9 million, a small but meaningful signal that the business is moving toward operating leverage even as it expands its molecular testing portfolio.

Curiously, EPS data and the EPS consensus weren’t supplied in the results release, so there’s no immediate earnings surprise story to compare against street expectations. Investors and analysts will watch closely for how the company frames profitability as it advances test mix and reimbursement dynamics in the quarters ahead.

Operational highlights driving the narrative

• RaDaR® ST launched: NeoGenomics unveiled a circulating tumor DNA (ctDNA) assay designed to detect molecular residual disease (MRD). Management pegs a roughly $20 billion addressable market for this category, with a growth trajectory around 30% annually and an estimated penetration well under 10%.
• Expansion of CGP offerings via PanTracer and related products: A favorable MolDX coverage decision for PanTracer LBx was announced, and the company introduced PanTracer Pro, expanding clinical pathways for therapy selection and trial enrollment in advanced solid tumors.
• Market and product narrative: Management frames RaDaR ST and PanTracer as key growth engines, signaling a shift toward higher clinical value assays that may translate into improved reimbursement and longer-term revenue resilience.

Guidance and near-term expectations

The company raised its full-year 2026 revenue forecast to a range of $797–$803 million, signaling confidence in mid-teens to low-double-digit growth trends embedded in its clinical testing and MRD-focused portfolio. The guidance tilt toward higher revenue alongside a still-narrow operating margin underscores a classic move for growth-oriented diagnostics firms: invest in high-visibility, high-value tests while chasing scale and payor acceptance. There isn’t a disclosed EPS target in this update, but the revenue raise effectively sets the bar for EPS realization to follow, assuming cost discipline complements top-line expansion.

What this means for NeoGenomics’ sector peers

NeoGenomics’ emphasis on MRD and ctDNA signals a broader shift in oncology diagnostics—where precision testing capabilities can pivot from research into routine clinical decision-making. If RaDaR ST gains traction and MolDX-like coverage expands for ctDNA-based tests, other assay developers and lab networks may recalibrate their product roadmaps toward MRD quantification and drug-diagnostic coupling. The earnings narrative now rests on how quickly such tests achieve payer acceptance, integration into standard care pathways, and favorable reimbursement cycles. In the near term, revenue forecast visibility could pressure peers to accelerate commercialization of similar MRD and CGP offerings, potentially affecting relative valuation in the sector as investors price in test mix quality and payor dynamics rather than just headline growth rates.

Risks and considerations

While the quarter shows resilience in clinical revenue and a clear pipeline in MRD and CGP, NeoGenomics remains a net loss company, with profitability contingent on higher-margin test adoption and operating leverage. Reimbursement risk, payer policy shifts, and competition from other oncology diagnostics players are ongoing headwinds. The pace at which RaDaR ST and PanTracer solutions translate into durable revenue, margin expansion, and EPS improvement will be the key questions for investors tracking the stock’s narrative and peer comparisons.

Bottom line

NeoGenomics is steering its ship toward higher-value oncology tests, betting on MRD-driven opportunities and expanded CGP coverage to push revenue higher in 2026. The absence of immediate EPS consensus data means that the near-term stock reaction may hinge on how convincingly management translates top-line momentum into profits and how quickly MRD-based offerings capture payer support. If RaDaR ST and PanTracer Pro become meaningful revenue contributors, the company could begin to demonstrate the operating leverage that has long eluded many growth-oriented diagnostic labs. In a sector where revenue forecast accuracy and test mix are as important as earnings surprises, NeoGenomics’ Q1 underscored a deliberate pivot toward durable, value-added tests—one that peers will watch with both curiosity and a bit of competitive anxiety.